KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Liabilities and Shareholders Equity: 2011-2025

Historic Liabilities and Shareholders Equity for Sarepta Therapeutics (SRPT) over the last 14 years, with Sep 2025 value amounting to $3.5 billion.

  • Sarepta Therapeutics' Liabilities and Shareholders Equity fell 2.96% to $3.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $14.6 billion, marking a year-over-year increase of 8.06%. This contributed to the annual value of $4.0 billion for FY2024, which is 21.40% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Liabilities and Shareholders Equity of $3.5 billion as of Q3 2025, which was down 5.06% from $3.7 billion recorded in Q2 2025.
  • Sarepta Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $4.0 billion during Q4 2024, with a 5-year trough of $2.7 billion in Q3 2021.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $3.4 billion (2024), whereas its average is $3.4 billion.
  • In the last 5 years, Sarepta Therapeutics' Liabilities and Shareholders Equity decreased by 6.18% in 2021 and then grew by 21.40% in 2024.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' Liabilities and Shareholders Equity stood at $3.1 billion in 2021, then decreased by 0.62% to $3.1 billion in 2022, then increased by 4.35% to $3.3 billion in 2023, then climbed by 21.40% to $4.0 billion in 2024, then fell by 2.96% to $3.5 billion in 2025.
  • Its Liabilities and Shareholders Equity was $3.5 billion in Q3 2025, compared to $3.7 billion in Q2 2025 and $3.5 billion in Q1 2025.